Is China’s biotech boom at risk? Fear of policy backlash after death in gene-editing trial

A six-year-old girl died after receiving an experimental gene-editing therapy, prompting calls for improved trial safeguards. The biotechnology industry fears Chinese policymakers may reduce regulatory flexibility, which has been critical to China's competitive edge in frontier treatments.